ASX Announcements

Dec 2021
Dec 1st, 2021
VIRALEZE™ registered in Vietnam with launch this week

Nov 2021
Nov 30th, 2021
AGM Results
Nov 30th, 2021
AGM Chairman address and CEO presentation
Nov 25th, 2021
Positive DEP® phase 2 interim results in prostate cancer
Nov 11th, 2021
Jobkeeper s323DB(1) notice
Nov 9th, 2021
Starpharma to present at Bell Potter Healthcare Conference
Nov 1st, 2021
Appendix 2A

Oct 2021
Oct 29th, 2021
Notice of Annual General Meeting/Proxy Form
Oct 29th, 2021
Quarterly Cashflow and Activities Report
Oct 28th, 2021
Starpharma to present DEP® at US Drug Delivery Conference
Oct 26th, 2021
VIRALEZE™ distribution and supply to Vietnam
Oct 25th, 2021
Appendix 3G
Oct 12th, 2021
VIRALEZE™ ADMENTA agreement - supplementary information
Oct 8th, 2021
VIRALEZE™ launch in ADMENTA Italia Group pharmacies in Italy
Oct 1st, 2021
2021 Annual General Meeting
Oct 1st, 2021
Appendix 3H (Notification of cessation of securities)
Oct 1st, 2021
Appendix 3Y

Sep 2021
Sep 15th, 2021
US patent issued for DEP cabazitaxel nanoparticle
Sep 13th, 2021
Appendix 2A

Aug 2021
Aug 31st, 2021
Change in Director's Interest Notice - Z Peach
Aug 30th, 2021
Change in Director's Interest Notice - J Fairley
Aug 27th, 2021
Change in Director's Interest Notice - R Thomas
Aug 27th, 2021
Change in Director's Interest Notice - L Cheng
Aug 26th, 2021
Appendix 4G – Corporate Governance Statement
Aug 26th, 2021
Starpharma annual report and full year financial results
Aug 23rd, 2021
VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
Aug 17th, 2021
VIRALEZE™ well tolerated in multiple dose clinical study
Aug 2nd, 2021
Initial Director's Interest Notice

Jul 2021
Jul 30th, 2021
Quarterly Cashflow and Activities Report
Jul 29th, 2021
Resignation of non-executive director
Jul 28th, 2021
Lynda Cheng appointed as non-executive director
Jul 27th, 2021
Starpharma to present DEP® platform at CRS Annual Meeting
Jul 27th, 2021
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
Jul 5th, 2021
TGA infringement notices for alleged advertising
Jul 2nd, 2021
Change in substantial holding

Jun 2021
Jun 24th, 2021
Starpharma to present at Virtual Life Sciences Investor Forum
Jun 21st, 2021
VIRALEZE UK update
Jun 18th, 2021
VIRALEZE SPL7013 virucidal against multiple COVID variants
Jun 11th, 2021
VIRALEZE antiviral nasal spray registered for sale in India
Jun 1st, 2021
VIRALEZE SPL7013 highly active in UK variant of coronavirus

May 2021
May 11th, 2021
VIRALEZE™ partners with Harlequins in the UK
May 6th, 2021
VIRALEZE™ launches in Europe

Apr 2021
Apr 28th, 2021
Shareholder Newsletter
Apr 27th, 2021
Quarterly Cashflow and Activities Report
Apr 9th, 2021
Appendix 2A

Mar 2021
Mar 30th, 2021
VIRALEZE™ now launched by LloydsPharmacy in the UK
Mar 25th, 2021
VIRALEZE™ to be launched with LloydsPharmacy in the UK
Mar 16th, 2021
DEP® HER2-lutetium outperforms in human breast cancer model
Mar 3rd, 2021
SPL7013 active against other pandemic coronaviruses

Feb 2021
Feb 25th, 2021
Interim Report and Half-Year Financial Results
Feb 23rd, 2021
VIRALEZE™ antiviral nasal spray registered in Europe
Feb 12th, 2021
Starpharma signs DEP® ADC Research Agreement with MSD
Feb 9th, 2021
AZD0466 clinical DEP® program global expansion
Feb 3rd, 2021
Change in substantial holding

Jan 2021
Jan 29th, 2021
Quarterly Cashflow and Activities Report
Jan 27th, 2021
Appendix 2A
Jan 18th, 2021
Change in substantial holding
Jan 18th, 2021
Change in substantial holding